Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA adverse event reporting system

Background To data, there is insufficient large-scale data on the adverse events (AEs) of pemigatinib. Consequently, we conducted a pharmacovigilance study utilizing the Food and Drug Administration Adverse Event Reporting System (FAERS) database to investigate these AEs.